Navigation Links
Isis Reports Financial Results and Highlights for Second Quarter of 2008
Date:8/7/2008

ted collaboration with GSK. As part of Regulus' strategic alliance with GSK, Regulus received a $15 million upfront fee, which it began amortizing into revenue in the second quarter of 2008 and will continue to amortize over its six-year period of performance under the agreement.

Excluding non-cash compensation expense related to stock options, operating expenses for Regulus were $1.8 million and $3.0 million for the three and six months ended June 30, 2008. With the recently announced strategic alliance with GSK, it is anticipated that Regulus' expenses will increase as Regulus continues to advance its research and development activities. The GSK alliance enhances Regulus' ability to expand operations and advance its programs. Regulus generated a loss from operations, excluding non-cash compensation expense related to stock options, of $1.2 million and $2.2 million for the three and six months ended June 30, 2008. Regulus' non-cash compensation expense related to stock options was $681,000 and $1.1 million for the three and six months ended June 30, 2008. Because Regulus was formed in the third quarter of 2007, it did not have operating results in the first half of 2007.

Quarterly Highlights

"Since the completion of our Genzyme collaboration, we've made great progress with mipomersen by initiating the first of four studies scheduled to begin by year end and receiving a patent allowance that gives the Isis-Genzyme Apolipoprotein B franchise broad protection of mipomersen and other antisense apoB compounds. In addition to the successes of our partnered drugs and satellite companies in the first half of the year, we continue to maximize the economic potential of our business model and our technology, while enabling the advancement of a broad portfolio of both partnered and internally developed drugs," concluded Ms. Parshall.

Cardiovascular Program

-- Completed licensing transaction for mipomersen

-- Finalized and announ
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related biology technology :

1. Barr Reports Second Quarter 2008 GAAP Earnings of $0.52 Per Share; Adjusted Earnings of $0.64 Per Share
2. PAREXEL Reports Fourth Quarter and Fiscal Year 2008 Financial Results
3. Caliper Life Sciences Reports Second Quarter 2008 Results
4. Watson Pharmaceuticals Reports Second Quarter 2008 Results
5. EntreMed Reports Second Quarter 2008 Financial Results
6. Transgenomic Reports Second Quarter 2008 Results
7. Onyx Pharmaceuticals Reports Second Quarter and Six-Month 2008 Financial Results
8. Bionovo Reports Second Quarter 2008 Financial Results
9. AtriCure Reports Record Second Quarter 2008 Financial Results
10. AMICAS Reports Financial Results for the Second Quarter Ended June 30, 2008
11. eResearchTechnology Reports Second Quarter 2008 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/23/2015)... Colo. , Jan. 23, 2015  Array BioPharma Inc. ... has reached a definitive agreement with Novartis Pharma AG ... inhibitor currently in Phase 3 development.  This agreement is conditional ... GlaxoSmithKline PLC (GSK) on April 22, 2014, which are expected ...
(Date:1/22/2015)... Davis, California (PRWEB) January 22, 2015 ... of Accelerator Mass Spectrometry (AMS) services to the pharmaceutical ... PhD has joined the company in the position of ... 30 years of broad and valuable experience in drug ...
(Date:1/22/2015)... RBJ today announces the firm brokered a long-term lease totaling ... biopharmaceutical company, at Two Ledgemont Center in Lexington, ... president, and Brian Cohen , senior vice president, represented ... 95 Hayden Ave. Photo - http://photos.prnewswire.com/prnh/20150122/170765 ...
(Date:1/22/2015)... 22, 2015  Transwestern | RBJ today announces the firm brokered ... for Shire a leading biopharmaceutical company, at Two Ledgemont Center ... Robert Richards , president, and Brian Cohen , ... entire five-floor building at 95 Hayden Ave. Photo ...
Breaking Biology Technology:Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 2Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 3Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 4Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 5Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 6Array Announces Agreement To Acquire ENCORAFENIB (LGX818) 7Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 2Eckert & Ziegler Vitalea Science appoints Mark Seymour, PhD as Director of Science & Technology 3Transwestern | RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2Transwestern?RBJ Advises Shire in 202,000 SF Lease, Creating Boston's Largest Suburban Biotech Campus 2
... Devgen,(Eurolist: DEVG) and Monsanto Company (NYSE: MON ... which Monsanto has agreed, subject to certain,customary conditions, to ... 18 million (25 million $) and representing 5.9%,of the ... take place,no later than November 2007. It is ...
... announces today,that a service agreement with Roche Diagnostics ... its automated immunohistochemistry,service platform for analyzing various biomarkers ... will provide for this project a selection of,tumor ... as specifically,collected clinical samples. The analysis of specific ...
... Nationally, SCOTTSDALE, Ariz., Sept. 14 CHS, an ... by the U.S. Department,of Defense as a recipient of ... award, sponsored by the National Committee of Employer,Support of ... honor,bestowed upon America,s employers who provide support to their ...
Cached Biology Technology:Monsanto Company Signs Share Subscription Agreement With Devgen 2Monsanto Company Signs Share Subscription Agreement With Devgen 3CHS Receives Prestigious Honor from Department of Defense 2CHS Receives Prestigious Honor from Department of Defense 3
(Date:12/24/2014)... , Dec. 23, 2014  Since its launch in December 2014, the ... eliminate the pain of trying to remember their usernames and ... fused to their smartphones. To assist people who have struggled ... company that created 1U and focuses on redefining identity, announced ...
(Date:12/19/2014)... Dec. 18, 2014 Research and Markets ( ... "iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire ... http://photos.prnewswire.com/prnh/20130307/600769 Following ... the fingerprint reading feature with the iPhone 5S. It ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... "Samsung Galaxy S5 - Home Button Synaptics Fingerprint ... http://photos.prnewswire.com/prnh/20130307/600769 Based ... 5S, Samsung introduces for the first time a fingerprint ...
Breaking Biology News(10 mins):1U Offers Best Solution to the Username / Password Dilemma: For FREE! 21U Offers Best Solution to the Username / Password Dilemma: For FREE! 3iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2
... <a target="_blank" href="http://en.wikipedia.org/wiki/Nucleic_acid_sequence,">DNA sequences come in various ... and discard compromised molecular data has thus become ... one that everyone generating sequence data is assumed ... research purposes. "Many researchers find sequence quality ...
... increasing salt concentrations are stress factors that many ecosystems ... do all ecosystems react to stress in the same ... services, such as biomass production? Botanists and ecologists from ... high level of biodiversity aids stress resistance. ...
... 5, 2012According to the Centers for Disease Control and ... has autism spectrum disorder (ASD), a broad group of ... fascinated by screen-based technology such as videogames and these ... described in an insightful Roundtable Discussion published ...
Cached Biology News:DNA sequences need quality time too - guidelines for quality control published 2Can videogaming benefit young people with autism spectrum disorder? 2
IC50: 3 ng/ml · Limit of detection: 0.9 ng/ml...
Request Info...
Request Info...
... Ambion's custom siRNA service provides the premium ... silencing research. Custom siRNAs can be readily ... base target sequence, or by providing the ... out Ambion's Silencer Validated and Silencer Pre-designed ...
Biology Products: